Tres Alchemix Raises $4.4M Series A to Advance AI Drug-Design Platform
AI-native biotech startup expands to Oxford to develop predictive models for safer, faster drug discovery
Fukuoka, Japan – October 3, 2025 – Tres Alchemix, a cutting-edge biotechnology company applying artificial intelligence (AI) to drug discovery, has closed a $4.4 million Series A funding round (approx. ¥650 million JPY), led by DNX Ventures, with support from Waseda University Ventures.
The funding will fuel the development of Tres Alchemix’s human in silico drug-design platform, a technology that integrates multi-omic datasets, quantum-chemical calculations, and AI modeling to simulate drug interactions in the human body. This enables direct predictions of both therapeutic effects and potential adverse reactions, dramatically improving the speed and safety of early drug discovery.
The company will also open a new R&D facility at The Oxford Science Park in the UK, strengthening its international footprint. The expansion follows the establishment of a UK-based subsidiary in 2024.
A Smarter Approach to Drug Design
Founded in 2023 by three DPhil graduates from the University of Oxford, Tres Alchemix is developing a unique platform to design novel small-molecule therapies with high precision. The platform can propose new drug candidates tailored to disease biology—significantly shortening the traditional hit-identification phase.
“We believe our technology can be a game changer for the drug-discovery field,” said Hisashi Hashimoto, CEO and Co-founder. “By predicting both efficacy and side effects before compounds ever enter the lab, we can reduce failure rates and accelerate discovery.”
The company’s initial focus is oncology, where predictive accuracy and time-to-clinic are critical.
Investor Confidence
Lead investor DNX Ventures emphasized the potential for Tres Alchemix’s platform to transform pharmaceutical R&D.
“These human in silico models simulate drug behavior in the body, enabling high-precision predictions,” said Akira Kurabayashi, Managing Partner at DNX.
“The co-founders bring a rare blend of expertise in medicine, computer science, and quantum chemistry. Their innovation could drive a global shift in how drugs are developed,” added Yoshiki Shiraishi, Partner at DNX.
International Expansion
While headquartered in Fukuoka, Japan, the company is scaling rapidly into the UK, attracted by Oxford’s deep scientific ecosystem. The new Oxford lab will serve as a hub for computational chemistry, AI model training, and compound design.
About Tres Alchemix
Tres Alchemix is an AI-native biotechnology company developing a predictive drug-design platform to create next-generation small-molecule therapies. By integrating multi-omic and multimodal datasets with proprietary quantum-chemical methods, it builds human in silico models that forecast both efficacy and safety. Founded in 2023, the company is based in Japan and expanding globally.
